Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC

Annachiara Mitrugno, Joanna L. Sylman, Anh T P Ngo, Jiaqing Pang, Rosalie Sears, Craig D. Williams, Owen McCarty

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Aspirin, an anti-inflammatory and antithrombotic drug, has become the focus of intense research as a potential anticancer agent owing to its ability to reduce tumor proliferation in vitro and to prevent tumorigenesis in patients. Studies have found an anticancer effect of aspirin when used in low, antiplatelet doses. However, the mechanisms through which low-dose aspirin works are poorly understood. In this study, we aimed to determine the effect of aspirin on the cross talk between platelets and cancer cells. For our study, we used two colon cancer cell lines isolated from the same donor but characterized by different metastatic potential, SW480 (nonmetastatic) and SW620 (metastatic) cancer cells, and a pancreatic cancer cell line, PANC-1 (nonmetastatic). We found that SW480 and PANC-1 cancer cell proliferation was potentiated by human platelets in a manner dependent on the upregulation and activation of the oncoprotein c-MYC. The ability of platelets to upregulate c-MYC and cancer cell proliferation was reversed by an antiplatelet concentration of aspirin. In conclusion, we show for the first time that inhibition of platelets by aspirin can affect their ability to induce cancer cell proliferation through the modulation of the c-MYC oncoprotein.

Original languageEnglish (US)
Pages (from-to)C176-C189
JournalAmerican Journal of Physiology - Cell Physiology
Volume312
Issue number2
DOIs
StatePublished - Feb 8 2017

Fingerprint

Oncogene Proteins
Pancreatic Neoplasms
Colonic Neoplasms
Aspirin
Blood Platelets
Cell Proliferation
Neoplasms
Up-Regulation
Therapeutics
Cell Line
Antineoplastic Agents
Carcinogenesis
Anti-Inflammatory Agents
Tissue Donors
Research
Pharmaceutical Preparations

Keywords

  • Aspirin
  • C-MYC
  • Cancer
  • Platelets
  • Proliferation

ASJC Scopus subject areas

  • Physiology
  • Cell Biology

Cite this

Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation : Implications for the oncoprotein c-MYC. / Mitrugno, Annachiara; Sylman, Joanna L.; Ngo, Anh T P; Pang, Jiaqing; Sears, Rosalie; Williams, Craig D.; McCarty, Owen.

In: American Journal of Physiology - Cell Physiology, Vol. 312, No. 2, 08.02.2017, p. C176-C189.

Research output: Contribution to journalArticle

@article{2dfe4f863de847eaba4863de5dd2cc4f,
title = "Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC",
abstract = "Aspirin, an anti-inflammatory and antithrombotic drug, has become the focus of intense research as a potential anticancer agent owing to its ability to reduce tumor proliferation in vitro and to prevent tumorigenesis in patients. Studies have found an anticancer effect of aspirin when used in low, antiplatelet doses. However, the mechanisms through which low-dose aspirin works are poorly understood. In this study, we aimed to determine the effect of aspirin on the cross talk between platelets and cancer cells. For our study, we used two colon cancer cell lines isolated from the same donor but characterized by different metastatic potential, SW480 (nonmetastatic) and SW620 (metastatic) cancer cells, and a pancreatic cancer cell line, PANC-1 (nonmetastatic). We found that SW480 and PANC-1 cancer cell proliferation was potentiated by human platelets in a manner dependent on the upregulation and activation of the oncoprotein c-MYC. The ability of platelets to upregulate c-MYC and cancer cell proliferation was reversed by an antiplatelet concentration of aspirin. In conclusion, we show for the first time that inhibition of platelets by aspirin can affect their ability to induce cancer cell proliferation through the modulation of the c-MYC oncoprotein.",
keywords = "Aspirin, C-MYC, Cancer, Platelets, Proliferation",
author = "Annachiara Mitrugno and Sylman, {Joanna L.} and Ngo, {Anh T P} and Jiaqing Pang and Rosalie Sears and Williams, {Craig D.} and Owen McCarty",
year = "2017",
month = "2",
day = "8",
doi = "10.1152/ajpcell.00196.2016",
language = "English (US)",
volume = "312",
pages = "C176--C189",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation

T2 - Implications for the oncoprotein c-MYC

AU - Mitrugno, Annachiara

AU - Sylman, Joanna L.

AU - Ngo, Anh T P

AU - Pang, Jiaqing

AU - Sears, Rosalie

AU - Williams, Craig D.

AU - McCarty, Owen

PY - 2017/2/8

Y1 - 2017/2/8

N2 - Aspirin, an anti-inflammatory and antithrombotic drug, has become the focus of intense research as a potential anticancer agent owing to its ability to reduce tumor proliferation in vitro and to prevent tumorigenesis in patients. Studies have found an anticancer effect of aspirin when used in low, antiplatelet doses. However, the mechanisms through which low-dose aspirin works are poorly understood. In this study, we aimed to determine the effect of aspirin on the cross talk between platelets and cancer cells. For our study, we used two colon cancer cell lines isolated from the same donor but characterized by different metastatic potential, SW480 (nonmetastatic) and SW620 (metastatic) cancer cells, and a pancreatic cancer cell line, PANC-1 (nonmetastatic). We found that SW480 and PANC-1 cancer cell proliferation was potentiated by human platelets in a manner dependent on the upregulation and activation of the oncoprotein c-MYC. The ability of platelets to upregulate c-MYC and cancer cell proliferation was reversed by an antiplatelet concentration of aspirin. In conclusion, we show for the first time that inhibition of platelets by aspirin can affect their ability to induce cancer cell proliferation through the modulation of the c-MYC oncoprotein.

AB - Aspirin, an anti-inflammatory and antithrombotic drug, has become the focus of intense research as a potential anticancer agent owing to its ability to reduce tumor proliferation in vitro and to prevent tumorigenesis in patients. Studies have found an anticancer effect of aspirin when used in low, antiplatelet doses. However, the mechanisms through which low-dose aspirin works are poorly understood. In this study, we aimed to determine the effect of aspirin on the cross talk between platelets and cancer cells. For our study, we used two colon cancer cell lines isolated from the same donor but characterized by different metastatic potential, SW480 (nonmetastatic) and SW620 (metastatic) cancer cells, and a pancreatic cancer cell line, PANC-1 (nonmetastatic). We found that SW480 and PANC-1 cancer cell proliferation was potentiated by human platelets in a manner dependent on the upregulation and activation of the oncoprotein c-MYC. The ability of platelets to upregulate c-MYC and cancer cell proliferation was reversed by an antiplatelet concentration of aspirin. In conclusion, we show for the first time that inhibition of platelets by aspirin can affect their ability to induce cancer cell proliferation through the modulation of the c-MYC oncoprotein.

KW - Aspirin

KW - C-MYC

KW - Cancer

KW - Platelets

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=85012066256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012066256&partnerID=8YFLogxK

U2 - 10.1152/ajpcell.00196.2016

DO - 10.1152/ajpcell.00196.2016

M3 - Article

C2 - 27903583

AN - SCOPUS:85012066256

VL - 312

SP - C176-C189

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 2

ER -